NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.
Stocks quotes in this article: NLNK, MACK, ADMS

Shares of NewLink Genetics Corp. (NLNK) rose 5.7% to $10.06 ahead of the market open on Monday, Oct. 30, after the U.S. Food and Drug Administration granted orphan drug designation to the Ames, Iowa-based firm's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.

In other news, the FDA gave orphan drug designation to Merrimack Pharmaceuticals Inc.'s (MACK) MM-121 for the treatment of heregulin positive non-small cell lung cancer. Shares of Cambridge, Mass.-based Merrimack were up 3.7% to $11.85.

Among the other stock movers was Adamas Pharmaceuticals Inc. (ADMS) , up 17.4% to $22.90. The Emeryville, Calif.-based company said on Oct. 25 that the FDA has recognized seven years of orphan drug exclusivity for Adamas' Gocovri (amantadine) extended release capsules.

The agency in August approved Gocovri as a treatment for dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

Here's My Risk and Reward Parameters for Vir Biotechnology

Bruce Kamich

Let's look over the charts and indicators.

Karuna Therapeutics Is Doing Important Research but Its Charts Are Weak

Bruce Kamich

The technical signals of the clinical-stage biotech company don't inspire confidence at this juncture.

Thrill Seekers Might Like 2 Downtrodden Stocks Insiders Are Buying

Bret Jensen

TherapeuticsMD and Spark Networks are beaten-down names with recent buying interest from insiders in common.

Market Participants Are Battling Omicron Pessimism

James "Rev Shark" DePorre

There are a number of issues to consider from a trading standpoint as we start the week.

Fingers Crossed for a Small-Cap Revenge Rally in 2022

Bret Jensen

The lingering effects of the pandemic have been hard on smaller biotech and healthcare stocks, but the worm could turn next year.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight